Fixed Drug Eruption after ChAdOx1 nCoV-19 Vaccine
Introduction: ChAdOx1 nCoV-19 vaccine is an adenoviral-vectored COVID-19 vaccine. The most common side effects are headache, muscle pain, redness, swelling, and tenderness at the injection site. Cutaneous reactions have been rarely reported. Objective: To discuss the association between a fixed drug...
Gespeichert in:
| Veröffentlicht in: | Drug safety 2022-10, Vol.45 (10), p.1197-1197 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1197 |
|---|---|
| container_issue | 10 |
| container_start_page | 1197 |
| container_title | Drug safety |
| container_volume | 45 |
| creator | Jabri, F E Kastalli, S Ferchichi, K Dabbeche, S Daghfous, R Aidli, S E |
| description | Introduction: ChAdOx1 nCoV-19 vaccine is an adenoviral-vectored COVID-19 vaccine. The most common side effects are headache, muscle pain, redness, swelling, and tenderness at the injection site. Cutaneous reactions have been rarely reported. Objective: To discuss the association between a fixed drug eruption (FDE) and ChAdOx1 nCoV-19 vaccine. Methods: We report one case of (FDE) following administration of the ChAdOx1 nCoV-19. Results: A 60-year-old man with no medical history and no regular medication presented with a rash that had appeared 24 hours after he had received his first dose of the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca). The lesions had appeared abruptly without any accompanying symptoms. Physical examination revealed three, well-defined, round to oval, erythematous to violaceous plaques in the face. A punch biopsy was taken, and histopathology findings were consistent with fixed drug eruption. Conclusion: This case shows that the fixed drug eruption can be a result of receiving the ChAdOx1 nCoV-19 vaccine (OxfordAstraZeneca). |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2718402181</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2718402181</sourcerecordid><originalsourceid>FETCH-proquest_journals_27184021813</originalsourceid><addsrcrecordid>eNpjYuA0NDS31DW0NDFiYeA0MDQ00TW1NDTjYOAqLs4yMDCwMDKz4GQwdMusSE1RcCkqTVdwLSotKMnMz1NITCtJLVJwznBM8a8wVMhzzg8DGqMQlpicnJmXysPAmpaYU5zKC6W5GZTdXEOcPXQLivILS1OLS-Kz8kuL8oBS8UbmhhYmBkaGFobGxKkCAMWrMvc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2718402181</pqid></control><display><type>article</type><title>Fixed Drug Eruption after ChAdOx1 nCoV-19 Vaccine</title><source>SpringerLink (Online service)</source><creator>Jabri, F E ; Kastalli, S ; Ferchichi, K ; Dabbeche, S ; Daghfous, R ; Aidli, S E</creator><creatorcontrib>Jabri, F E ; Kastalli, S ; Ferchichi, K ; Dabbeche, S ; Daghfous, R ; Aidli, S E</creatorcontrib><description>Introduction: ChAdOx1 nCoV-19 vaccine is an adenoviral-vectored COVID-19 vaccine. The most common side effects are headache, muscle pain, redness, swelling, and tenderness at the injection site. Cutaneous reactions have been rarely reported. Objective: To discuss the association between a fixed drug eruption (FDE) and ChAdOx1 nCoV-19 vaccine. Methods: We report one case of (FDE) following administration of the ChAdOx1 nCoV-19. Results: A 60-year-old man with no medical history and no regular medication presented with a rash that had appeared 24 hours after he had received his first dose of the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca). The lesions had appeared abruptly without any accompanying symptoms. Physical examination revealed three, well-defined, round to oval, erythematous to violaceous plaques in the face. A punch biopsy was taken, and histopathology findings were consistent with fixed drug eruption. Conclusion: This case shows that the fixed drug eruption can be a result of receiving the ChAdOx1 nCoV-19 vaccine (OxfordAstraZeneca).</description><identifier>ISSN: 0114-5916</identifier><identifier>EISSN: 1179-1942</identifier><language>eng</language><publisher>Auckland: Springer Nature B.V</publisher><subject>Biopsy ; Coronaviruses ; COVID-19 vaccines ; Eruptions ; Headache ; Histopathology ; Muscles ; Pain ; Plaques ; Side effects ; Skin eruptions ; Vaccines</subject><ispartof>Drug safety, 2022-10, Vol.45 (10), p.1197-1197</ispartof><rights>Copyright Springer Nature B.V. Oct 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Jabri, F E</creatorcontrib><creatorcontrib>Kastalli, S</creatorcontrib><creatorcontrib>Ferchichi, K</creatorcontrib><creatorcontrib>Dabbeche, S</creatorcontrib><creatorcontrib>Daghfous, R</creatorcontrib><creatorcontrib>Aidli, S E</creatorcontrib><title>Fixed Drug Eruption after ChAdOx1 nCoV-19 Vaccine</title><title>Drug safety</title><description>Introduction: ChAdOx1 nCoV-19 vaccine is an adenoviral-vectored COVID-19 vaccine. The most common side effects are headache, muscle pain, redness, swelling, and tenderness at the injection site. Cutaneous reactions have been rarely reported. Objective: To discuss the association between a fixed drug eruption (FDE) and ChAdOx1 nCoV-19 vaccine. Methods: We report one case of (FDE) following administration of the ChAdOx1 nCoV-19. Results: A 60-year-old man with no medical history and no regular medication presented with a rash that had appeared 24 hours after he had received his first dose of the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca). The lesions had appeared abruptly without any accompanying symptoms. Physical examination revealed three, well-defined, round to oval, erythematous to violaceous plaques in the face. A punch biopsy was taken, and histopathology findings were consistent with fixed drug eruption. Conclusion: This case shows that the fixed drug eruption can be a result of receiving the ChAdOx1 nCoV-19 vaccine (OxfordAstraZeneca).</description><subject>Biopsy</subject><subject>Coronaviruses</subject><subject>COVID-19 vaccines</subject><subject>Eruptions</subject><subject>Headache</subject><subject>Histopathology</subject><subject>Muscles</subject><subject>Pain</subject><subject>Plaques</subject><subject>Side effects</subject><subject>Skin eruptions</subject><subject>Vaccines</subject><issn>0114-5916</issn><issn>1179-1942</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpjYuA0NDS31DW0NDFiYeA0MDQ00TW1NDTjYOAqLs4yMDCwMDKz4GQwdMusSE1RcCkqTVdwLSotKMnMz1NITCtJLVJwznBM8a8wVMhzzg8DGqMQlpicnJmXysPAmpaYU5zKC6W5GZTdXEOcPXQLivILS1OLS-Kz8kuL8oBS8UbmhhYmBkaGFobGxKkCAMWrMvc</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Jabri, F E</creator><creator>Kastalli, S</creator><creator>Ferchichi, K</creator><creator>Dabbeche, S</creator><creator>Daghfous, R</creator><creator>Aidli, S E</creator><general>Springer Nature B.V</general><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7T2</scope><scope>7TK</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20221001</creationdate><title>Fixed Drug Eruption after ChAdOx1 nCoV-19 Vaccine</title><author>Jabri, F E ; Kastalli, S ; Ferchichi, K ; Dabbeche, S ; Daghfous, R ; Aidli, S E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_27184021813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biopsy</topic><topic>Coronaviruses</topic><topic>COVID-19 vaccines</topic><topic>Eruptions</topic><topic>Headache</topic><topic>Histopathology</topic><topic>Muscles</topic><topic>Pain</topic><topic>Plaques</topic><topic>Side effects</topic><topic>Skin eruptions</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jabri, F E</creatorcontrib><creatorcontrib>Kastalli, S</creatorcontrib><creatorcontrib>Ferchichi, K</creatorcontrib><creatorcontrib>Dabbeche, S</creatorcontrib><creatorcontrib>Daghfous, R</creatorcontrib><creatorcontrib>Aidli, S E</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jabri, F E</au><au>Kastalli, S</au><au>Ferchichi, K</au><au>Dabbeche, S</au><au>Daghfous, R</au><au>Aidli, S E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fixed Drug Eruption after ChAdOx1 nCoV-19 Vaccine</atitle><jtitle>Drug safety</jtitle><date>2022-10-01</date><risdate>2022</risdate><volume>45</volume><issue>10</issue><spage>1197</spage><epage>1197</epage><pages>1197-1197</pages><issn>0114-5916</issn><eissn>1179-1942</eissn><abstract>Introduction: ChAdOx1 nCoV-19 vaccine is an adenoviral-vectored COVID-19 vaccine. The most common side effects are headache, muscle pain, redness, swelling, and tenderness at the injection site. Cutaneous reactions have been rarely reported. Objective: To discuss the association between a fixed drug eruption (FDE) and ChAdOx1 nCoV-19 vaccine. Methods: We report one case of (FDE) following administration of the ChAdOx1 nCoV-19. Results: A 60-year-old man with no medical history and no regular medication presented with a rash that had appeared 24 hours after he had received his first dose of the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca). The lesions had appeared abruptly without any accompanying symptoms. Physical examination revealed three, well-defined, round to oval, erythematous to violaceous plaques in the face. A punch biopsy was taken, and histopathology findings were consistent with fixed drug eruption. Conclusion: This case shows that the fixed drug eruption can be a result of receiving the ChAdOx1 nCoV-19 vaccine (OxfordAstraZeneca).</abstract><cop>Auckland</cop><pub>Springer Nature B.V</pub></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0114-5916 |
| ispartof | Drug safety, 2022-10, Vol.45 (10), p.1197-1197 |
| issn | 0114-5916 1179-1942 |
| language | eng |
| recordid | cdi_proquest_journals_2718402181 |
| source | SpringerLink (Online service) |
| subjects | Biopsy Coronaviruses COVID-19 vaccines Eruptions Headache Histopathology Muscles Pain Plaques Side effects Skin eruptions Vaccines |
| title | Fixed Drug Eruption after ChAdOx1 nCoV-19 Vaccine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T09%3A01%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fixed%20Drug%20Eruption%20after%20ChAdOx1%20nCoV-19%20Vaccine&rft.jtitle=Drug%20safety&rft.au=Jabri,%20F%20E&rft.date=2022-10-01&rft.volume=45&rft.issue=10&rft.spage=1197&rft.epage=1197&rft.pages=1197-1197&rft.issn=0114-5916&rft.eissn=1179-1942&rft_id=info:doi/&rft_dat=%3Cproquest%3E2718402181%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2718402181&rft_id=info:pmid/&rfr_iscdi=true |